Dapagliflozin + Empagliflozin for heart failure, systolic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Oct 2023: Trial registered, NCT06065280

The trials

NCT06065280: Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

State
Completed
Phase
No phase
People
80 taking part
Started
1 Nov 2022
Primary completion
1 Dec 2024
Arms
Diabetic/HFrEF Group, Nondiabetic/HFrEF Group
Results
None posted
  1. 1 Nov 2022: Trial started
  2. 3 Oct 2023: Trial registered
  3. 30 Dec 2024: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.